SCLS
MCID: CPL003
MIFTS: 55

Capillary Leak Syndrome (SCLS)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases

Aliases & Classifications for Capillary Leak Syndrome

MalaCards integrated aliases for Capillary Leak Syndrome:

Name: Capillary Leak Syndrome 12 52 58 54 15 17 71
Systemic Capillary Leak Syndrome 52 58 17
Clarkson Disease 52 58
Scls 52 58
Capillary Leak Syndrome with Monoclonal Gammopathy 52
Periodic Systemic Capillary Leak Syndrome 52
Capillary Hyperpermeability Syndrome 58
Idiopathic Capillary Leak Syndrome 58

Characteristics:

Orphanet epidemiological data:

58
systemic capillary leak syndrome
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases


Summaries for Capillary Leak Syndrome

NIH Rare Diseases : 52 Systemic capillary leak syndrome (SCLS) is a condition in which fluid and proteins leak out of tiny blood vessels, into surrounding tissues . This can result in dangerously low blood pressure (hypotensison), hypoalbuminemia , and a decrease in plasma volume (hemoconcentration ). Initial symptoms may include fatigue, nausea, abdominal pain, extreme thirst, and sudden increase in body weight. Episodes of SCLS vary in frequency, with some people having one episode in their lifetime, and others having several per year. The severity also varies, and the condition can be fatal. In many cases the cause is not known (idiopathic SCLS). Some people with SCLS report having had an infection (such as a virus ) before the episode. Some cases of capillary leak are associated with various conditions of the heart, kidney, or liver. Treatment during an episode may involve stabilizing the airway and breathing, and infusion of fluids, medications, or blood products. Periodic infusions or the use of certain medications may be used to prevent future episodes.

MalaCards based summary : Capillary Leak Syndrome, also known as systemic capillary leak syndrome, is related to interstitial lung disease and angioedema. An important gene associated with Capillary Leak Syndrome is IL2 (Interleukin 2), and among its related pathways/superpathways are Innate Immune System and Pathways in cancer. The drugs Colchicine and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and kidney, and related phenotypes are pedal edema and leukocytosis

Wikipedia : 74 Capillary leak syndrome is characterized by the escape of blood plasma through capillary walls, from the... more...

Related Diseases for Capillary Leak Syndrome

Diseases related to Capillary Leak Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 515)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 30.9 IL6 CXCL8 CSF2 ALB
2 angioedema 30.9 SERPING1 C4A C1S
3 toxic shock syndrome 30.7 IL6 IL2 EDNRA CXCL8 C1S
4 fasciitis 30.7 IL6 IL2 CXCL8
5 pericarditis 30.6 IL6 CXCL8 ALB
6 brucellosis 30.5 IL6 IL2 CXCL8
7 hydrops, lactic acidosis, and sideroblastic anemia 30.5 SERPING1 C1S ALB
8 engraftment syndrome 30.5 CXCL8 CSF2
9 severe acute respiratory syndrome 30.4 IL6 IL2 CXCL8
10 diarrhea 30.4 IL6 IL2 CXCL8 C3 ALB
11 endocarditis 30.3 IL6 CXCL8 ALB
12 acquired angioedema 30.3 SERPING1 C3 C1S
13 necrotizing fasciitis 30.3 IL6 IL2 CXCL8 ALB
14 respiratory failure 30.3 IL6 ELANE CXCL8 ALB ADM
15 kawasaki disease 30.2 IL6 IL2 ELANE ALB ADM
16 adult respiratory distress syndrome 30.1 IL6 ELANE CXCL8 C4A
17 acute pancreatitis 30.1 IL6 ELANE CXCL8 ALB
18 vasculitis 30.1 IL6 ELANE C3 C1S
19 hemolytic uremic syndrome, atypical 1 30.1 SERPING1 C4A C3 C1S
20 thrombocytopenia 30.0 IL6 IL2 CXCL8 CSF2 C3 ALB
21 neutropenia 29.9 IL6 IL2 ELANE CXCL8 CSF2 ALB
22 hereditary angioedema 29.9 SERPING1 ELANE C4A C1S
23 glomerulonephritis 29.9 ELANE C4A C3 C1S ALB
24 pulmonary hypertension 29.9 IL6 ELANE EDNRA CXCL8 ALB ADM
25 rhinitis 29.8 IL6 ICOSLG CXCL8 CSF2 ALB
26 aspergillosis 29.8 IL6 IL15 ELANE CXCL8 CSF2
27 kidney cancer 29.7 IL2 ICOSLG CXCL8 CSF2 ALB
28 meningitis 29.7 IL6 IL2 CXCL8 CSF2 C3 ALB
29 pneumocystosis 29.7 IL6 CD8A CARTPT ALB
30 cellulitis 29.7 IL6 IL2 ICOSLG CD8A
31 peripheral nervous system disease 29.6 IL6 IL2 ICOSLG CXCL8 CD8A ALB
32 monoclonal gammopathy of uncertain significance 29.6 IL6 ICOSLG CD19
33 connective tissue disease 29.4 IL6 ICOSLG EDNRA CXCL8 CD8A ALB
34 lung disease 29.3 IL6 IL15 ELANE CXCL8 CSF2 CD8A
35 acute leukemia 29.2 IL3RA IL2 CSF2 CD8A CD22
36 exanthem 29.1 IL6 IL2 ICOSLG CXCL8 CSF2 CD8A
37 pancytopenia 29.0 IL6 CSF2 CD8A CD19 ALB
38 skin disease 28.9 SERPING1 IL6 IL2 ICOSLG CXCL8 CD8A
39 pneumonia 28.7 IL6 IL2 ELANE CXCL8 CSF2 CD8A
40 severe combined immunodeficiency 28.6 IL6 IL2 IL15 ICOSLG CSF2 CD19
41 autoimmune disease 28.6 IL6 IL2 IL15 ICOSLG CXCL8 CSF2
42 malaria 27.8 IL6 IL2 IL15 ICOSLG ELANE EDNRA
43 lymphoma, non-hodgkin, familial 27.1 IL6 IL2 IL15 ICOSLG CSF2 CD8A
44 leukemia, acute lymphoblastic 27.0 IL3RA IL2 ICOSLG CSF2 CD8A CD22
45 myeloma, multiple 26.9 IL6 IL2 IL15 ICOSLG CXCL8 CSF2
46 leukemia, chronic lymphocytic 26.2 IL6 IL3RA IL2 IL15 ICOSLG CSF2
47 leukemia, acute myeloid 26.2 IL6 IL3RA IL2 IL15 ICOSLG CXCL8
48 systemic lupus erythematosus 26.1 IL6 IL2 IL15 ICOSLG ELANE CXCL8
49 dengue disease 11.3
50 superior limbic keratoconjunctivitis 11.3

Graphical network of the top 20 diseases related to Capillary Leak Syndrome:



Diseases related to Capillary Leak Syndrome

Symptoms & Phenotypes for Capillary Leak Syndrome

Human phenotypes related to Capillary Leak Syndrome:

58 31 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pedal edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010741
2 leukocytosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001974
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
5 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
6 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
7 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
8 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
9 pancreatitis 58 31 frequent (33%) Frequent (79-30%) HP:0001733
10 pulmonary edema 58 31 frequent (33%) Frequent (79-30%) HP:0100598
11 rhinorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0031417
12 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
13 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
14 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
15 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
16 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
17 myocarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012819
18 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
19 oliguria 58 31 occasional (7.5%) Occasional (29-5%) HP:0100520
20 multiple myeloma 58 31 occasional (7.5%) Occasional (29-5%) HP:0006775
21 cardiorespiratory arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0006543
22 abnormal renal tubule morphology 31 occasional (7.5%) HP:0000091
23 abnormality of the renal tubule 58 Occasional (29-5%)
24 constitutional symptom 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB C3 C4A CD22 CXCL8 IL3RA

MGI Mouse Phenotypes related to Capillary Leak Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 ADM C3 CARTPT CD19 CD22 CD8A
2 cellular MP:0005384 10.14 ADM ALB C3 CD19 CD22 CD8A
3 cardiovascular system MP:0005385 10.13 ADM ALB C3 CD19 CSF2 EDNRA
4 immune system MP:0005387 10.13 ADM ALB C3 CARTPT CD19 CD22
5 endocrine/exocrine gland MP:0005379 10.11 ADM ALB C3 CARTPT CD8A CSF2
6 mortality/aging MP:0010768 9.97 ADM ALB C3 CD19 CD22 CD8A
7 neoplasm MP:0002006 9.5 ALB CD19 CSF2 ELANE IL2 IL6
8 renal/urinary system MP:0005367 9.28 ADM ALB C3 CD19 CD8A CSF2

Drugs & Therapeutics for Capillary Leak Syndrome

Drugs for Capillary Leak Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colchicine Approved Phase 2 64-86-8 2833 6167
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
4
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
5
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
6
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
7
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
8 Molgramostim Investigational Phase 2 99283-10-0
9 Tubulin Modulators Phase 2
10 Antirheumatic Agents Phase 2
11 Antimitotic Agents Phase 2
12 Immunoglobulins Phase 2
13 Antibodies Phase 2
14 Antibodies, Monoclonal Phase 2
15 Ch14.18 monoclonal antibody Phase 2
16 Anti-Infective Agents Phase 2
17 Immunotoxin HA22 Phase 2
18 Immunotoxins Phase 2
19 Anti-HIV Agents Phase 2
20 Analgesics, Non-Narcotic Phase 2
21 Antiviral Agents Phase 2
22 Interleukin-2 Phase 2
23 Analgesics Phase 2
24 Dermatologic Agents Phase 2
25 Anti-Retroviral Agents Phase 2
26 Immunologic Factors Phase 2
27 Keratolytic Agents Phase 2
28
Clofarabine Approved, Investigational Phase 1 123318-82-1 119182
29
Etoposide Approved Phase 1 33419-42-0 36462
30
rituximab Approved Phase 1 174722-31-7 10201696
31 Gastrointestinal Agents Phase 1
32 Etoposide phosphate Phase 1
33 Hormones Phase 1
34 Antineoplastic Agents, Hormonal Phase 1
35 Alkylating Agents Phase 1
36 Antiemetics Phase 1
37 Hormone Antagonists Phase 1
38 BB 1101 Phase 1
39 glucocorticoids Phase 1
40 Antimetabolites Phase 1
41 Anti-Inflammatory Agents Phase 1
42 Bendamustine Hydrochloride Phase 1
43 Antineoplastic Agents, Immunological Phase 1
44
Ciprofloxacin Approved, Investigational 85721-33-1 2764
45
Meropenem Approved, Investigational 96036-03-2, 119478-56-7 441130 64778
46
Tazobactam Approved 89786-04-9 123630
47
Clavulanate Approved, Vet_approved 58001-44-8 5280980
48
Amoxicillin Approved, Vet_approved 26787-78-0 33613
49
Vancomycin Approved 1404-90-6 14969 441141
50
Piperacillin Approved 66258-76-2 43672

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia Recruiting NCT04322565 Phase 2 Colchicine
2 A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT02338050 Phase 2
3 Randomized Phase 2 Trial Comparing Experimental Immunotherapy in Recurrent High Risk Neuroblastoma Patients With Standard Immunotherapy in Patients With Recurrent and Newly Diagnosed High Risk Neuroblastoma Terminated NCT02641782 Phase 2 antibody ch14.18;GM-CSF;IL-2 i.v.;IL-2 s.c.;Retinoic acid
4 A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01900509 Phase 1 Bendamustine;Clofarabine;Etoposide;Etoposide phosphate;Dexamethasone
5 A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma Completed NCT00889408 Phase 1
6 A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Rituximab (Rituxan (R)) for Relapsed Hairy Cell Leukemia Recruiting NCT03805932 Phase 1 Moxetumomab Pasudotox-tdfk
7 Effects of Intraoperative Goal-Directed Fluid Therapy on the Incidence of Postoperative Complications Following Gastrointestinal Surgery Unknown status NCT02507557
8 Meropenem and Ciprofloxacin Dosing in the Critically Ill Patient With Septic Shock - a Single Center Pharmacokinetic Study Unknown status NCT02240277
9 Evaluation of the Association Between Pre-existing Endothelial Dysfunction and the Onset of Vasoplegia During Cardiac Surgery With Cardiopulmonary Bypass Unknown status NCT02965339
10 Monitoring the IMmUological TOXicity of Drugs Completed NCT03480529 drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
11 Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients Completed NCT03410771 Monitor antibiotic exposure (PK profile)
12 Topical Autologous Serum Eye Drops Combined With Silicone Hydrogen Lenses for theTreatment of Corneal Epithelial Defects Completed NCT02291731 Continuous use of topical autologous serum
13 Serum Albumin, Colloid Osmotic Pressure and Endothelial Damage in Patients With End Stage Liver Disease Undergoing Orthotopic Liver Transplantation. A Retrospective Data Analysis. Completed NCT03448679
14 Contact Lens Assessment in Youth - Soft Contacts Observation of Risk and Education (CLAY-SCORE) Completed NCT03305484
15 Studies in the Pathogenesis of Systemic Capillary Leak Syndrome Recruiting NCT00936325
16 Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation Recruiting NCT03135496
17 US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM) Recruiting NCT04125290
18 Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19) Recruiting NCT04361526
19 Vasoplegia During VA-ECMO for Refractory Cardiogenic Shock : Descriptive Analysis of a Retrospective Cohort Recruiting NCT03968926
20 Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery Active, not recruiting NCT02853682
21 A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta Active, not recruiting NCT04253015
22 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514

Search NIH Clinical Center for Capillary Leak Syndrome

Genetic Tests for Capillary Leak Syndrome

Anatomical Context for Capillary Leak Syndrome

MalaCards organs/tissues related to Capillary Leak Syndrome:

40
Endothelial, Liver, Kidney, Heart, Bone, Bone Marrow, Lung

Publications for Capillary Leak Syndrome

Articles related to Capillary Leak Syndrome:

(show top 50) (show all 693)
# Title Authors PMID Year
1
Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. 61 52
28602874 2017
2
The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction. 61 54
18496242 2008
3
Left posterior fascicular block due to high-dose interleukin-2. 54 61
18664608 2008
4
Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich's Syndrome). 61 54
17085290 2006
5
Validation of C1-esterase inhibitor therapy in severe capillary leak syndrome by monitoring of extravascular lung water. 61 54
14727019 2004
6
[Idiopathic anaphylaxis]. 54 61
15015747 2004
7
Managing toxicities of high-dose interleukin-2. 54 61
12469935 2002
8
Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinoma. 61 54
12400987 2002
9
Interleukin-2 as a therapeutic agent. 61 54
11837757 2001
10
Anticancer drug-induced kidney disorders. 54 61
11219485 2001
11
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2. 61 54
11022123 2000
12
Pulmonary infiltrates after cytokine therapy for stem cell transplantation. Massive deposition of eosinophil major basic protein detected by immunohistochemistry. 61 54
10508829 1999
13
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. 61 54
10554800 1999
14
Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. 54 61
9383227 1997
15
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. 61 54
9815532 1997
16
Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. 54 61
8674057 1996
17
Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome? 61 54
9414399 1996
18
The release of interleukin-8 during intravenous bolus treatment with interleukin-2. 61 54
7696165 1994
19
Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. 61 54
8012963 1994
20
Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. 54 61
8110879 1994
21
Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. 54 61
8439951 1993
22
[Anatomopathological findings correlated with high-dose recombinant interleukin-2. Review of the literature and description of 2 autopsy cases]. 61 54
1491889 1992
23
Interleukin-2 therapy enhances salicylate oxidation by blood granulocytes. 54 61
1954382 1991
24
Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. 61 54
1884020 1991
25
[Interleukin immunotherapy of progression]. 54 61
1830670 1991
26
Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. 61 54
1760811 1991
27
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. 54 61
2093734 1990
28
Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. 54 61
2224143 1990
29
[The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro]. 61 54
2376610 1990
30
Effect of human recombinant interleukin-2 on isolated rabbit femoral artery and porcine coronary artery and vein. 61 54
2282064 1990
31
Pathophysiology of cytokines. 61 54
2201818 1990
32
A Case of Prolonged Angioedema After Cardiac Surgery. 61
31948888 2020
33
The effects of severe hemoconcentration on acid-base equilibrium in critically ill patients: the forgotten role of buffers in whole blood. 61
32171088 2020
34
Near-fatal poisoning after ricin injection. 61
32475181 2020
35
Pulmonary Capillary Leak Syndrome following COVID-19 Virus Infection. 61
32519786 2020
36
[Severe noncardiogenic pulmonary edema due to permeability disorder after i.v. administration of CT contrast medium with subsequent venovenous extracorporeal membrane oxygenation]. 61
32548721 2020
37
Myocardial edema in paroxysmal permeability disorders: The paradigm of Clarkson's disease. 61
32006896 2020
38
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. 61
32336420 2020
39
Vascular effects of cancer treatments. 61
32539632 2020
40
Key Regulatory Effect of Activated HIF-1α/VEGFA Signaling Pathway in Systemic Capillary Leak Syndrome Confirmed by Bioinformatics Analysis. 61
31545077 2020
41
Capillary leak syndrome: often forgotten in differential diagnosis. 61
32395941 2020
42
SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome (Clarkson's Disease). 61
32405072 2020
43
Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment. 61
32432565 2020
44
Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma. 61
32356686 2020
45
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. 61
32460559 2020
46
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. 61
31944549 2020
47
A case report of capillary leak syndrome with recurrent pericardial and pleural effusions. 61
32352064 2020
48
Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres. 61
32113688 2020
49
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. 61
32317293 2020
50
Predictors of Reopening the Sternum in Children After Cardiac Surgery. 61
31702705 2020

Variations for Capillary Leak Syndrome

Expression for Capillary Leak Syndrome

Search GEO for disease gene expression data for Capillary Leak Syndrome.

Pathways for Capillary Leak Syndrome

Pathways related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 IL6 IL3RA IL2 IL15 ICOSLG ELANE
2 12.7 IL6 IL3RA IL2 IL15 EDNRA CXCL8
3
Show member pathways
12.67 IL6 IL2 IL15 ICOSLG CXCL8 CD8A
4
Show member pathways
12.34 IL6 IL3RA IL2 IL15 CSF2
5 12.24 IL6 IL2 IL15 CSF2
6 12.17 IL6 ELANE CXCL8 CSF2
7
Show member pathways
12.06 SERPING1 C4A C3 C1S
8 12 SERPING1 C4A C3 C1S
9 11.96 CD8A CD22 CD19 C3
10 11.75 IL6 IL15 CXCL8 CSF2
11 11.73 IL6 IL3RA CSF2 CD8A CD22 CD19
12
Show member pathways
11.7 C4A C3 C1S
13 11.69 IL2 IL15 CD8A
14 11.67 IL6 IL2 CXCL8 CSF2
15
Show member pathways
11.66 IL2 CXCL8 CSF2
16 11.57 IL6 CXCL8 CSF2
17
Show member pathways
11.53 IL6 IL2 CXCL8 CSF2
18 11.51 IL6 CXCL8 C3
19 11.51 SERPING1 IL6 CXCL8 C4A C3 C1S
20 11.43 IL6 CXCL8 CSF2
21 11.3 IL6 IL3RA IL2 CSF2 CD8A CD19
22 11.29 IL6 IL3RA IL2 IL15 CSF2 CD8A
23
Show member pathways
11.24 IL2 IL15 CSF2
24 11.13 IL6 IL2 IL15 CSF2

GO Terms for Capillary Leak Syndrome

Cellular components related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.87 IL6 IL2 ELANE EDNRA CD19 CARTPT
2 extracellular region GO:0005576 9.8 SERPING1 IL6 IL2 IL15 ELANE CXCL8
3 external side of plasma membrane GO:0009897 9.65 IL3RA ICOSLG CD8A CD22 CD19
4 blood microparticle GO:0072562 9.55 SERPING1 C4A C3 C1S ALB
5 extracellular space GO:0005615 9.44 SERPING1 IL6 IL2 IL15 ELANE CXCL8

Biological processes related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 IL6 C4A C3 ALB
2 cytokine-mediated signaling pathway GO:0019221 9.8 IL6 IL3RA IL2 CXCL8 CSF2
3 inflammatory response GO:0006954 9.8 IL6 IL15 CXCL8 C4A C3 ADM
4 regulation of immune response GO:0050776 9.77 ICOSLG CD8A CD22 CD19 C3
5 complement activation, classical pathway GO:0006958 9.76 SERPING1 C4A C3 C1S
6 immune response GO:0006955 9.7 IL6 IL2 IL15 CXCL8 CSF2 CD8A
7 positive regulation of T cell proliferation GO:0042102 9.69 IL6 IL2 IL15
8 positive regulation of immune response GO:0050778 9.56 IL15 ELANE
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 IL6 IL2 IL15 CSF2
10 immune system process GO:0002376 9.56 SERPING1 IL2 ICOSLG CD8A CD19 C4A
11 positive regulation of immunoglobulin secretion GO:0051024 9.55 IL6 IL2
12 neutrophil activation GO:0042119 9.54 IL15 CXCL8
13 positive regulation of apoptotic cell clearance GO:2000427 9.49 C4A C3
14 positive regulation of tissue remodeling GO:0034105 9.48 IL2 IL15
15 negative regulation of chemokine biosynthetic process GO:0045079 9.43 IL6 ELANE
16 regulation of complement activation GO:0030449 9.02 SERPING1 CD19 C4A C3 C1S

Molecular functions related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TPX2 SERPING1 IL6 IL3RA IL2 IL15
2 cytokine activity GO:0005125 9.02 IL6 IL2 IL15 CXCL8 CSF2

Sources for Capillary Leak Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....